SCHEMBL20764115

SCHEMBL20764115

O=C(Nc1ccc(Cl)cc1)c1ccc(-c2ccsc2)s1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESRRG P62508 10/20 0.78
▸ ESR1 P03372 3/20 0.67
▸ ESR2 Q92731 2/20 0.64
▸ NPC1 O15118 2/20 0.56
▸ PPARG P37231 2/20 0.56
▸ RAB9A P51151 2/20 0.56
▸ KDM4E B2RXH2 2/20 0.56
▸ NR2E3 Q9Y5X4 1/20 0.56
▸ NCOR2 Q9Y618 1/20 0.56
▸ MAPKAPK2 P49137 1/20 0.55
▸ NCOA2 Q15596 1/20 0.54
▸ NCOA1 Q15788 1/20 0.54
▸ NCOA3 Q9Y6Q9 1/20 0.54
▸ PRSS12 P56730 1/20 0.52
▸ LMNA P02545 2/20 0.51
▸ RXFP1 Q9HBX9 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ CNR1 P21554 1/20 0.51
▸ PTPN11 Q06124 2/20 0.50
▸ HTT P42858 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20764063 0.88 ESRRG (1.00) ESRRGESR1ESR2NPC1PPARG
SCHEMBL22311188 0.84 ESRRG (0.74) ESRRGESR1ESR2NPC1PPARG
SCHEMBL20764069 0.84 ESRRG (0.74) ESRRGESR1ESR2NPC1PPARG
SCHEMBL20764040 0.83 SMN1; SMN2 (0.76) ESRRGESR1ESR2NPC1PPARG
SCHEMBL4930772 0.82 ESRRG (0.73) ESRRGESR1ESR2NPC1PPARG
SCHEMBL20764016 0.81 ESRRG (1.00) ESRRGESR1ESR2NPC1PPARG
SCHEMBL20764080 0.80 ESRRG (0.78) ESRRGESR1ESR2NPC1PPARG
SCHEMBL20764030 0.78 ESRRG (1.00) ESRRGESR1ESR2NPC1PPARG
SCHEMBL20764092 0.77 ESRRG (0.65) ESRRGESR1ESR2NPC1PPARG
SCHEMBL20764102 0.76 ESRRG (0.72) ESRRGESR1ESR2NPC1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200247792-A1 ERR INVERSE AGONISTS SAINT LOUIS UNIVERSITY (US) 2020-08-06 — — US disclosed
WO-2019036562-A1 ERR INVERSE AGONISTS SAINT LOUIS UNIVERSITY (US) 2019-02-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200247792-A1 ERR INVERSE AGONISTS ESRRA, ESRRB, ESR2 ESRRG 4/4885ESR1 6/4885ESR2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback